Joshua Schafer's most recent trade in Zevra Therapeutics Inc was a trade of 10,500 Common Stock done at an average price of $9.2 . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Sale of securities on an exchange or to another person at price $ 9.19 per share. | 03 Feb 2026 | 10,500 | 62,278 (0%) | 0% | 9.2 | 96,500 | Common Stock |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 37,500 | 37,500 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 35,334 | 35,333 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 35,334 | 72,778 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 11,333 | 22,667 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 11,333 | 40,819 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO | Sale of securities on an exchange or to another person at price $ 8.83 per share. | 29 Jan 2026 | 3,375 | 37,444 (0%) | 0% | 8.8 | 29,800 | Common Stock |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Sale of securities on an exchange or to another person at price $ 7.86 per share. | 13 Feb 2025 | 10,500 | 29,486 (0%) | 0% | 7.9 | 82,527 | Common Stock |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 68,000 | 68,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 35,333 | 39,986 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 35,333 | 70,667 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 34,000 | 34,000 | - | - | Restricted Stock Unit | |
| Shuttle Pharma Holdings Inc | Joshua Schafer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 209,790 | 210,004 | - | 0 | Common Stock | |
| Shuttle Pharma Holdings Inc | Joshua Schafer | Director | 31 Dec 2024 | 209,790 | 210,004 | - | 0 | Common Stock | ||
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 106,000 | 106,000 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 19 May 2023 | 1,000 | 3,000 (0%) | 0% | 5.4 | 5,416 | Common Stock |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Purchase of securities on an exchange or from another person at price $ 4.61 per share. | 14 Mar 2023 | 2,000 | 2,000 (0%) | 0% | 4.6 | 9,218 | Common Stock |
| Zevra Therapeutics Inc | Joshua Schafer | CCO & EVP, Bus. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 300,000 | 300,000 | - | - | Stock Option (right to buy) |